Avacta seeks to raise £5m to buy new reagents platform
This article was originally published in Clinica
Executive Summary
Analysis and detection technologies specialist Avacta is looking to raise around £5m ($7.7m) in new capital to help finance its planned acquisition of AptuScan, a fellow UK company with a proprietary reagents platform.